Gulayse Ince-Dunn

Gulayse Ince-Dunn

Auto-generated profile, based on publicly available information

Gulayse Ince-Dunn

Stem Cells and Metabolism, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Neuron
Verified
Journal Article
Closed access
GIGulayse Ince-Dunn
Gulayse Ince-Dunn
HOHirotaka James Okano
Hirotaka James Okano
KJKirk B. Jensen
Kirk B. Jensen
WPWoong-Yang Park
Woong-Yang Park
RZRu Zhong
Ru Zhong
RDRobert B. Darnell
Robert B. Darnell

9 January 2004 in Science
Verified
Journal Article
Closed access
PDF file
HAHiroyuki Aizawa
Hiroyuki Aizawa
SHShu-Ching Hu
Shu-Ching Hu
KBKathryn Bobb
Kathryn Bobb
KBKarthik Balakrishnan
Karthik Balakrishnan
GIGulayse Ince
Gulayse Ince
AGAnirvan Ghosh
Anirvan Ghosh
The lasting effects of neuronal activity on brain development involve calcium-dependent gene expression. Using a strategy called transactivator trap, we cloned a calcium-responsive transactivator called CREST (for calcium-responsive transactivator). CREST is a SYT-related nuclear protein that interacts with adenosine 3′,5′-monophosphate (cAMP) response element–binding protein (CREB)–binding protein (CBP) and is expressed in the developing brain. Mice that have a targeted disruption of the crest gene are viable but display defects in cortical and hippocampal dendrite development. Cortical neurons from crest mutant mice are compromised in calcium-dependent dendritic growth. Thus, calcium activation of CREST-mediated transcription helps regulate neuronal morphogenesis.

1 May 2007 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
FPFranck Polleux
Franck Polleux
GIGulayse Ince-Dunn
Gulayse Ince-Dunn
AGAnirvan Ghosh
Anirvan Ghosh

1 March 2006 in Neuron
Verified
Journal Article
Closed access
GIGulayse Ince-Dunn
Gulayse Ince-Dunn
BHBenjamin J. Hall
Benjamin J. Hall
SHShu-Ching Hu
Shu-Ching Hu
BRBeth Ripley
Beth Ripley
RHRichard L. Huganir
Richard L. Huganir
AGAnirvan Ghosh
Anirvan Ghosh

16 November 2022 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
OIOlesia Ignatenko
Olesia Ignatenko
SMSatu Malinen
Satu Malinen
SRSofiia Rybas
Sofiia Rybas
HVHelena Vihinen
Helena Vihinen
JNJoni Nikkanen
Joni Nikkanen
ASAnu Suomalainen
Anu Suomalainen
Astrocytes, often considered as secondary responders to neurodegeneration, are emerging as primary drivers of brain disease. Here we show that mitochondrial DNA depletion in astrocytes affects their primary cilium, the signaling organelle of a cell. The progressive oxidative phosphorylation deficiency in astrocytes induces FOXJ1 and RFX transcription factors, known as master regulators of motile ciliogenesis. Consequently, a robust gene expression program involving motile cilia components and multiciliated cell differentiation factors are induced. While the affected astrocytes still retain a single cilium, these organelles elongate and become remarkably distorted. The data suggest that chronic activation of the mitochondrial integrated stress response (ISRmt) in astrocytes drives anabolic metabolism and promotes ciliary elongation. Collectively, our evidence indicates that an active signaling axis involving mitochondria and primary cilia exists and that ciliary signaling is part of ISRmt in astrocytes. We propose that metabolic ciliopathy is a novel pathomechanism for mitochondria-related neurodegenerative diseases.

2 January 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
SKSofia Khan
Sofia Khan
GIGulayse Ince-Dunn
Gulayse Ince-Dunn
ASAnu Suomalainen
Anu Suomalainen
LELaura L. Elo
Laura L. Elo
High-throughput technologies for genomics, transcriptomics, proteomics, and metabolomics, and integrative analysis of these data, enable new, systems-level insights into disease pathogenesis. Mitochondrial diseases are an excellent target for hypothesis-generating omics approaches, as the disease group is mechanistically exceptionally complex. Although the genetic background in mitochondrial diseases is in either the nuclear or the mitochondrial genome, the typical downstream effect is dysfunction of the mitochondrial respiratory chain. However, the clinical manifestations show unprecedented variability, including either systemic or tissue-specific effects across multiple organ systems, with mild to severe symptoms, and occurring at any age. So far, the omics approaches have provided mechanistic understanding of tissue-specificity and potential treatment options for mitochondrial diseases, such as metabolome remodeling. However, no curative treatments exist, suggesting that novel approaches are needed. In this Review, we discuss omics approaches and discoveries with the potential to elucidate mechanisms of and therapies for mitochondrial diseases.